Product logins

Find logins to all Clarivate products below.


John Stahl​

Partner​, US Pricing and Market Access​

John Stahl is a Partner with Clarivate’s Commercial Strategy Consulting team and leads the US Pricing and Market Access practice.​

John leverages over 20 years of deep healthcare knowledge as well as a broad range of market access and commercialization experience to effectively deliver strategic and actionable insights to biopharmaceutical and medtech clients. John has been with Clarivate for 10+ years, and during this time, he has supported clients with the development of market access landscape assessments, evidence generation and value communication strategies, pricing and contracting strategies, and account engagement strategies and tactics. His experience spans numerous TAs, with a concentration in cell and gene therapy, rare disease, oncology, immunology, and neurology conditions.​

Prior to joining Clarivate, John spent over ten years in the pharmaceutical industry working for Johnson & Johnson and Novartis, in a variety of positions of increasing responsibility, including business analytics, business development, sales, marketing, and managed markets.

John graduated from Duke University with a B.A. in Economics and a B.A. in German. He also completed the Certificate program in Markets and Management Studies.​


arrow_forward
Get in touch with John

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全